Boothbay Fund Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-9,688
Closed -$109K 2549
2022
Q2
$109K Sell
9,688
-16,327
-63% -$328K ﹤0.01% 1960
2022
Q1
$778K Buy
26,015
+21,041
+423% +$570K 0.02% 1057
2021
Q4
$132K Sell
4,974
-1,678
-25% -$50.6K ﹤0.01% 1651
2021
Q3
$241K Sell
6,652
-194
-3% -$7.64K 0.01% 1465
2021
Q2
$297K Buy
6,846
+3,214
+88% +$121K 0.01% 1289
2021
Q1
$124K Sell
3,632
-4,873
-57% -$193K ﹤0.01% 1452
2020
Q4
$298K Sell
8,505
-12,377
-59% -$358K 0.01% 950
2020
Q3
$501K Sell
20,882
-2,403
-10% -$59K 0.03% 643
2020
Q2
$426K Buy
23,285
+1,580
+7% +$28.4K 0.03% 617
2020
Q1
$339K Buy
21,705
+15,344
+241% +$327K 0.03% 543
2019
Q4
$136K Buy
+6,361
New +$131K 0.01% 735
2016
Q4
Sell
-1,516
Closed -$56K 908
2016
Q3
$56K Sell
1,516
-1,567
-51% -$44.9K 0.01% 681
2016
Q2
$69K Sell
3,083
-78
-2% -$1.94K 0.03% 475
2016
Q1
$66K Buy
3,161
+704
+29% +$17.4K 0.05% 276
2015
Q4
$74K Buy
2,457
+750
+44% +$22.7K 0.03% 518
2015
Q3
$42K Buy
1,707
+571
+50% +$17K 0.02% 430
2015
Q2
$36K Hold
1,136
0.01% 394
2015
Q1
$41K Buy
+1,136
New +$31.1K 0.03% 317

Other funds holding RIGL

Boothbay Fund Management's RIGL Position: Q3 2022 in Review

Boothbay Fund Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 9,688 shares — an estimated $109K sold.

Boothbay Fund Management first reported a position in RIGL in Q1 2015 and held it in 18 quarters. The position peaked at $778K in Q1 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

  • Boothbay Fund Management reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 9,688 Rigel Pharmaceuticals shares in Q3 2022, an estimated $109K.
  • Boothbay Fund Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 18 quarters.
  • Boothbay Fund Management's Rigel Pharmaceuticals position peaked at $778K in Q1 2022.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.